Last reviewed: June 26, 2026
Last updated: June 26, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Patients managing both opioid use disorder and weight loss may wonder if naltrexone and semaglutide can work together safely. Current clinical evidence shows no direct pharmacokinetic interaction between these two compounds, but combination therapy requires individualized assessment and close provider monitoring to optimize outcomes.
How Naltrexone and Semaglutide Work Differently
Naltrexone is an opioid receptor antagonist developed to reduce cravings and block euphoric effects in opioid use disorder. Semaglutide, by contrast, activates glucagon-like peptide-1 (GLP-1) receptors in the brain and pancreas to regulate appetite, blood sugar, and weight. Because these medications target entirely separate neurological pathways, they do not compete for metabolic processing or receptor binding.
The two drugs use different elimination routes: naltrexone is metabolized hepatically through glucuronidation, while semaglutide undergoes enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase. This pharmacokinetic separation means neither medication significantly alters the blood concentration or effectiveness of the other at standard therapeutic doses.
Clinical Evidence on Naltrexone-Semaglutide Drug Interactions
Peer-reviewed literature has not documented clinically significant direct pharmacokinetic interactions between naltrexone and GLP-1 receptor agonists. A 2023 analysis of adverse event reporting systems found no unexpected safety signals when both agents were prescribed concurrently in real-world settings. The FDA has not issued warnings or contraindications against combined use.
However, both medications can independently affect gastrointestinal function and appetite signaling. Semaglutide commonly causes nausea, vomiting, and decreased appetite during dose escalation, while naltrexone may trigger gastrointestinal side effects in some patients. Overlapping symptoms—particularly nausea or constipation—require careful symptom tracking to distinguish between drug-specific and combination effects.
Why Medical Oversight Matters for Dual Therapy
Combining naltrexone with semaglutide demands informed prescriber judgment because the medications address distinct but sometimes interconnected health goals. A patient on naltrexone for opioid disorder may have underlying metabolic dysfunction, cardiovascular risk, or psychiatric comorbidities that influence GLP-1 therapy safety and efficacy. Providers must evaluate baseline kidney function, liver health, and existing medications before initiating combination treatment.
PlexusDx partners with licensed prescribers who conduct comprehensive medical histories and assess medication compatibility before dispensing compounded semaglutide. This personalized review ensures that naltrexone dosing, duration, and formulation (oral vs. extended-release) are factored into GLP-1 protocol selection and dose titration schedules.
Optimizing Weight Loss With Personalized GLP-1 Selection
Patients combining naltrexone with weight-loss therapy benefit from genetic insight into their peptide-pathway response. PlexusDx offers the Precision Peptide Genetic Test, which analyzes variants in GLP1R, GIPR, FTO, and MC4R genes to predict individual responsiveness to semaglutide versus tirzepatide. This 14-pathway, 150+ genetic-insight analysis helps prescribers match the right compound and starting dose for maximum efficacy.
PlexusDx Semaglutide Injection starts at $149 per month with a flat-rate pricing model—meaning your dose may increase as treatment progresses, but your monthly cost will not rise beyond your chosen tier. This pricing transparency removes barriers to safe dose optimization, particularly for patients managing multiple chronic conditions like opioid use disorder and obesity simultaneously.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I take naltrexone and semaglutide (Ozempic) at the same time?
Yes, current clinical evidence does not show a direct pharmacokinetic interaction between naltrexone and semaglutide. However, combination therapy requires prescriber oversight to monitor for overlapping gastrointestinal side effects and ensure both medications are appropriate for your individual health status. PlexusDx coordinates with your prescriber to review your complete medical history before dispensing.
Do naltrexone and GLP-1 drugs compete in the liver or interact through metabolism?
No. Naltrexone undergoes hepatic glucuronidation, while semaglutide is metabolized through enzymatic peptidase degradation. These separate elimination pathways mean neither drug significantly alters the other's blood levels or clearance rate, reducing the risk of accumulation or reduced efficacy.
What side effects should I watch for if I use both medications?
Both naltrexone and semaglutide can cause nausea, vomiting, and appetite changes. Monitor for unusual gastrointestinal symptoms, and report them promptly to your prescriber so they can determine whether to adjust dose timing, formulation, or drug schedule. PlexusDx provides ongoing patient support to track tolerability.
How much does PlexusDx Semaglutide Injection cost if I'm on naltrexone?
PlexusDx Semaglutide Injection starts at $149 per month with a flat-rate pricing model—your dose may increase without raising your monthly cost. PlexusDx serves all 50 states without requiring insurance, and treatment is HSA/FSA eligible, making it accessible alongside other medications you may be taking.
Can the Precision Peptide Genetic Test help predict my response if I'm on naltrexone?
Yes. The Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R variants to predict your individual responsiveness to semaglutide or tirzepatide, informing optimal compound and dose selection. This personalized insight is particularly valuable for patients managing multiple conditions, as it helps ensure your weight-loss therapy aligns with your unique genetic pathway profile.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Beyond the Scale: How Does Wegovy Help With Inflammation for Better Health?
Does Zepbound Hurt When Injected? Understanding the Experience